Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Clinical trial NCT04662255 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04662255
Sponsor: Loxo Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Lymphoma, Mantle-Cell

Start date: 2021-04-08
Primary completion: 2027-01-01
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.